Literature DB >> 33542467

Full-length in meso structure and mechanism of rat kynurenine 3-monooxygenase inhibition.

Shinya Mimasu1, Hiroaki Yamagishi2,3, Satoshi Kubo2, Mie Kiyohara2, Toshihiro Matsuda2, Toshiko Yahata2, Heather A Thomson4, Christopher D Hupp4, Julie Liu4,5, Takao Okuda2,6, Kenichi Kakefuda2.   

Abstract

The structural mechanisms of single-pass transmembrane enzymes remain elusive. Kynurenine 3-monooxygenase (KMO) is a mitochondrial protein involved in the eukaryotic tryptophan catabolic pathway and is linked to various diseases. Here, we report the mammalian full-length structure of KMO in its membrane-embedded form, complexed with compound 3 (identified internally) and compound 4 (identified via DNA-encoded chemical library screening) at 3.0 Å resolution. Despite predictions suggesting that KMO has two transmembrane domains, we show that KMO is actually a single-pass transmembrane protein, with the other transmembrane domain lying laterally along the membrane, where it forms part of the ligand-binding pocket. Further exploration of compound 3 led to identification of the brain-penetrant compound, 5. We show that KMO is dimeric, and that mutations at the dimeric interface abolish its activity. These results will provide insight for the drug discovery of additional blood-brain-barrier molecules, and help illuminate the complex biology behind single-pass transmembrane enzymes.

Entities:  

Year:  2021        PMID: 33542467      PMCID: PMC7862291          DOI: 10.1038/s42003-021-01666-5

Source DB:  PubMed          Journal:  Commun Biol        ISSN: 2399-3642


  42 in total

1.  Structural Basis for Inhibitor-Induced Hydrogen Peroxide Production by Kynurenine 3-Monooxygenase.

Authors:  Hyun Tae Kim; Byeong Kwan Na; Jiwoung Chung; Sulhee Kim; Sool Ki Kwon; Hyunju Cha; Jonghyeon Son; Joong Myung Cho; Kwang Yeon Hwang
Journal:  Cell Chem Biol       Date:  2018-02-08       Impact factor: 8.116

2.  Lead discovery for human kynurenine 3-monooxygenase by high-throughput RapidFire mass spectrometry.

Authors:  Denise M Lowe; Michelle Gee; Carl Haslam; Bill Leavens; Erica Christodoulou; Paul Hissey; Philip Hardwicke; Argyrides Argyrou; Scott P Webster; Damian J Mole; Kris Wilson; Margaret Binnie; Beverley A Yard; Tony Dean; John Liddle; Iain Uings; Jonathan P Hutchinson
Journal:  J Biomol Screen       Date:  2013-12-31

3.  A genomic screen in yeast implicates kynurenine 3-monooxygenase as a therapeutic target for Huntington disease.

Authors:  Flaviano Giorgini; Paolo Guidetti; QuangVu Nguyen; Simone C Bennett; Paul J Muchowski
Journal:  Nat Genet       Date:  2005-04-03       Impact factor: 38.330

4.  The inhibition of the kynurenine pathway prevents behavioral disturbances and oxidative stress in the brain of adult rats subjected to an animal model of schizophrenia.

Authors:  Gislaine Z Réus; Indianara R T Becker; Giselli Scaini; Fabricia Petronilho; Jean P Oses; Rima Kaddurah-Daouk; Luciane B Ceretta; Alexandra I Zugno; Felipe Dal-Pizzol; João Quevedo; Tatiana Barichello
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2017-10-13       Impact factor: 5.067

5.  Development of a series of aryl pyrimidine kynurenine monooxygenase inhibitors as potential therapeutic agents for the treatment of Huntington's disease.

Authors:  Leticia M Toledo-Sherman; Michael E Prime; Ladislav Mrzljak; Maria G Beconi; Alan Beresford; Frederick A Brookfield; Christopher J Brown; Isabell Cardaun; Stephen M Courtney; Ulrike Dijkman; Estelle Hamelin-Flegg; Peter D Johnson; Valerie Kempf; Kathy Lyons; Kimberly Matthews; William L Mitchell; Catherine O'Connell; Paula Pena; Kendall Powell; Arash Rassoulpour; Laura Reed; Wolfgang Reindl; Suganathan Selvaratnam; Weslyn Ward Friley; Derek A Weddell; Naomi E Went; Patricia Wheelan; Christin Winkler; Dirk Winkler; John Wityak; Christopher J Yarnold; Dawn Yates; Ignacio Munoz-Sanjuan; Celia Dominguez
Journal:  J Med Chem       Date:  2015-01-23       Impact factor: 7.446

Review 6.  Targeting kynurenine 3-monooxygenase (KMO): implications for therapy in Huntington's disease.

Authors:  Mathuravani A Thevandavakkam; Robert Schwarcz; Paul J Muchowski; Flaviano Giorgini
Journal:  CNS Neurol Disord Drug Targets       Date:  2010-12       Impact factor: 4.388

7.  Crystallizing membrane proteins using lipidic mesophases.

Authors:  Martin Caffrey; Vadim Cherezov
Journal:  Nat Protoc       Date:  2009       Impact factor: 13.491

8.  Development of LC/MS/MS, high-throughput enzymatic and cellular assays for the characterization of compounds that inhibit kynurenine monooxygenase (KMO).

Authors:  Dirk Winkler; Maria Beconi; Leticia M Toledo-Sherman; Michael Prime; Andreas Ebneth; Celia Dominguez; Ignacio Muñoz-Sanjuan
Journal:  J Biomol Screen       Date:  2013-05-20

9.  Overview of the CCP4 suite and current developments.

Authors:  Martyn D Winn; Charles C Ballard; Kevin D Cowtan; Eleanor J Dodson; Paul Emsley; Phil R Evans; Ronan M Keegan; Eugene B Krissinel; Andrew G W Leslie; Airlie McCoy; Stuart J McNicholas; Garib N Murshudov; Navraj S Pannu; Elizabeth A Potterton; Harold R Powell; Randy J Read; Alexei Vagin; Keith S Wilson
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2011-03-18

10.  Increased breakdown of kynurenine towards its neurotoxic branch in bipolar disorder.

Authors:  Armin Birner; Martina Platzer; Susanne Astrid Bengesser; Nina Dalkner; Frederike T Fellendorf; Robert Queissner; Rene Pilz; Philipp Rauch; Alexander Maget; Carlo Hamm; Simone Herzog-Eberhard; Harald Mangge; Dietmar Fuchs; Natalie Moll; Sieglinde Zelzer; Gregor Schütze; Markus Schwarz; Bernd Reininghaus; Hans-Peter Kapfhammer; Eva Z Reininghaus
Journal:  PLoS One       Date:  2017-02-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.